The National Heart, Lung, and Blood Institute, part of the National Institutes of Health, has ended the Transcranial Doppler with Transfusions Changing to Hydroxyurea clinical trial early in arrangement with the recommendations of the Data and Safety Monitoring Board. The TWiTCH research looked for to figure out whether providing day-to-day doses of hydroxyurea reduces the TCD blood velocity in children with sickle cell disease to a comparable level as blood transfusions. Children with sickle cell disease that go to a higher risk for stroke are recognized by measuring the speed of blood flow to the brain by TCD ultrasound studies. Children with the highest possible TCD velocities have a greater risk of strokes. The early review revealed that hydroxyurea decreases TCD blood velocities to a similar degree as blood transfusions. The outcomes of this research study reveal that hydroxyurea is not inferior to routine blood transfusions in reducing TCD speeds in children with sickle cell disease that are at high risk for stroke.
* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions
** If you believe that content on the Plex is summarised improperly, please, contact us, and we will get rid of it quickly; please, send an email with a brief explanation.